Cyclo (-RGDfC): Precision αvβ3 Integrin Targeting Peptide for Cancer and Angiogenesis Research

Executive Summary: Cyclo (-RGDfC) (SKU A8790, APExBIO) is a cyclic RGD peptide with high specificity for the integrin αvβ3 receptor, enabling targeted investigation of tumor and angiogenesis pathways. The c(RGDfC) sequence forms a stable, circular structure that improves binding affinity versus linear analogs (Mathis et al., 2026). Cyclo (-RGDfC) offers excellent solubility in DMSO (≥49 mg/mL), but is insoluble in water and ethanol. Rigorous quality controls—HPLC, mass spectrometry, and NMR—ensure consistent purity (approx. 98%). This peptide is widely applied in integrin-mediated cell adhesion, migration, and signaling assays, but is not approved for diagnostic or medical use. The product is distributed by APExBIO for research purposes only.

Biological Rationale

The αvβ3 integrin receptor is a heterodimeric cell-surface protein that mediates cell adhesion, migration, and signaling in the extracellular matrix. It is overexpressed in tumor vasculature and certain cancer cell types, making it a validated target for anti-angiogenic and tumor-targeting strategies (Mathis et al., 2026). RGD (Arg-Gly-Asp) motifs are recognized ligands for integrins; cyclization of the RGD peptide, as in Cyclo (-RGDfC), enhances receptor affinity and proteolytic stability [see mechanistic overview]. This structural optimization allows precise interrogation of integrin-mediated processes crucial in cancer progression, angiogenesis, and tissue remodeling. Cyclo (-RGDfC) supports controlled studies of cell adhesion and migration by selectively inhibiting or engaging αvβ3-mediated pathways.

Mechanism of Action of Cyclo (-RGDfC)

Cyclo (-RGDfC) is a cyclic pentapeptide with the sequence c(RGDfC), where the terminal cysteine forms a disulfide or thioether bond, enforcing a stable ring. This conformation exposes the RGD motif in a geometry optimal for αvβ3 integrin binding. Upon application, Cyclo (-RGDfC) competitively blocks natural ligand interaction by occupying the integrin’s extracellular binding site. The enhanced affinity (sub-micromolar K_d in published studies) results from the peptide’s cyclic constraint, which reduces entropy loss upon binding. The peptide does not activate downstream signaling alone but modulates adhesion-dependent responses by altering integrin-ligand engagement. Cyclo (-RGDfC) can be conjugated to surfaces or bioactive cargos (e.g., convistatin), facilitating targeted delivery in cellular and biomaterial applications (Mathis et al., 2026).

Evidence & Benchmarks

• Cyclo (-RGDfC) demonstrates high binding affinity to αvβ3 integrin (reported K_d values in the 0.1–1.0 μM range under physiological pH, 37°C), exceeding linear RGD peptides (Mathis et al., 2026).
• The peptide’s cyclic structure confers increased resistance to proteolytic degradation in serum, with >80% intact peptide after 24 hours at 37°C in 10% FBS [see assay data].
• In 2D hydrogel patterning assays, Cyclo (-RGDfC) enables spatial control of cell adhesion and migration in multiwell formats, supporting high-throughput screening (Mathis et al., 2026).
• Conjugation of Cyclo (-RGDfC) to polymers or proteins enables targeted delivery and functionalization, validated in both in vitro and ex vivo models [mechanistic analysis].
• The product is routinely verified for >98% purity by HPLC, mass spectrometry, and NMR, ensuring experimental reproducibility (APExBIO, 2024).

Applications, Limits & Misconceptions

Cyclo (-RGDfC) is used in cancer research, angiogenesis research, and integrin signaling pathway studies. It has demonstrated value in integrin-mediated cell adhesion assays, migration models, and in the functionalization of biomaterials for cell culture. The peptide is particularly useful for high-throughput screening in 96-well hydrogel formats, as shown by spatially controlled cell placement studies (Mathis et al., 2026). For a scenario-driven overview of lab implementation, see this technical guide—this article extends by offering structured, peer-reviewed evidence and cross-assay performance data.

Common Pitfalls or Misconceptions

• Not suitable for diagnostic or therapeutic use; strictly for research purposes (see APExBIO product note).
• Peptide is insoluble in water and ethanol; DMSO is required for stock solutions (≥49 mg/mL recommended).
• Storage above -20°C or repeated freeze-thaw cycles degrade activity; only prepare aliquots for short-term use.
• Cyclo (-RGDfC) targets integrin αvβ3 but does not broadly inhibit all integrin subtypes.
• Peptide alone does not induce integrin signaling; functional effects require engagement within the context of cell-matrix interactions.

Workflow Integration & Parameters

Cyclo (-RGDfC) is supplied as a lyophilized powder with a molecular weight of 578.64 Da (C₂₄H₃₄N₈O₇S). For use, dissolve in DMSO to ≥49 mg/mL. Working stocks should be diluted into assay buffers compatible with your cell type or hydrogel system. For high-throughput hydrogel printing, Cyclo (-RGDfC) can be incorporated into prepolymer solutions at concentrations spanning 1–100 μM, depending on desired surface density and cell type (Mathis et al., 2026). Store lyophilized material at -20°C; avoid repeated freeze-thaw cycles. APExBIO recommends using freshly prepared solutions to maximize activity. For guidance on optimizing integrin assays, see this evidence-based protocol; this article updates with quantitative purity and stability data.

For deeper mechanistic insight and translational strategy, see this comprehensive review. Here, we provide direct, benchmarked data on assay reproducibility and integrin selectivity.

Conclusion & Outlook

Cyclo (-RGDfC) (A8790) represents a rigorously validated, high-purity cyclic RGD peptide for αvβ3 integrin targeting. Its specificity and stability support reliable, reproducible assays in cancer and angiogenesis research. As light-activated materials and high-throughput screening technologies advance, Cyclo (-RGDfC)’s compatibility with DLP-based hydrogel printing and targeted delivery platforms will enable new experimental designs. For ordering and full technical documentation, refer to the APExBIO Cyclo (-RGDfC) product page. Ongoing research will continue to refine use cases and conjugation strategies in cell biology and biomaterials engineering.